fbpx
    • ASCO
    • Multiple Myeloma News
    • Jun 18, 2019

    ASCO 2019: Venetoclax Updates with Mike Thompson, MD, PhD, Advocate Aurora Health

image_print

Venetoclax is the first drug that was determined to work for a specific type of genetic feature found in multiple myeloma patients called the 11;14 translocation. This means that part of chromosome 11 has swapped places with parts of chromosome 14 on the myeloma cells. This is the most common translocation found in myeloma patients (20% of patients) and is found to be a standard risk feature. Venetoclax works as a BCL-2 inhibitor and other relapsed or refractory myeloma patients can respond to it as well. 

In a Phase 1/2 study (ECOG-ACRIN EAA172), researchers compared daratumumab/bortezomib/dex with daratumumab/bortezomb/dex/venetoclax. In these early studies, safety and dosing are always the goal. This study went on clinical hold (meaning it could not recruit new patients) because of data that came out in a separate study using venetoclax with bortezomib and dex (the BELLINI trial). 

Combination therapy with daratumumab and bortezomib (DVd) has become a standard of care in relapsed/refractory myeloma and the hypothesis is that adding venetoclax could improve outcomes, especially for the t(11;14) patients.

In the Phase II study, 240 patients will be included with 1/3 of patients having t(11;14) and 2/3 of patients having no t(11;14). Investigators are looking forward to the continuation and results of this study. 

 

 

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

Leave A Comment

Please enter the correct captcha code to verify that you are human.

MYELOMA CROWD RESEARCH INITIATIVE
$165328 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: